Most patients with differentiated thyroid cancer fall into low risk stages, where survival is >90%. Therefore, for these patients, initial stratification for structural disease risk for recurrence should be the primary determinant for therapeutic decision-making about surgery, radioiodine, and TSH suppression.
After primary therapy, surveillance data from serum thyroglobulin testing and ultrasound imaging can be used to guide long-term follow-up.
After this session, you will be given the tools to:
• Recognize how to determine risks for both structural recurrence and disease-specific mortality based upon initial staging of patients with differentiated thyroid cancer.
• Apply evidence-based recommendations to decision making about extent of surgery, I131 therapy and TSH suppression.
• Utilize results from surveillance imaging and thyroglobulin testing to determine long-term follow-up strategies.